Proton beam therapy in Japan: current and future status

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Proton beam therapy (PBT) use has grown in Japan since 2000, with 11 facilities operational by 2016.
• PBT is crucial for pediatric cancers due to the need to minimize radiation effects on growth and development.
• Hepatocellular carcinoma, common in Asia, and nasal/skull base lesions are key areas for PBT application.

Purpose of the Study:

• To review the current applications and future potential of proton beam therapy in Japan.
• To highlight PBT's benefits in reducing radiation dose to critical organs, particularly in pediatric patients.
• To identify areas requiring further clinical investigation, including combination therapies and cost-effectiveness.

Main Methods:

• Review of existing literature and clinical practices regarding proton beam therapy in Japan.
• Analysis of PBT's efficacy and safety in treating various cancers, including pediatric, liver, head/neck, and prostate.
• Exploration of emerging applications, such as chemoproton therapy.

Main Results:

• PBT is effective for pediatric cancers, liver cancer (especially in Asia), and nasal/skull base tumors, reducing dose to sensitive organs.
• Comparative studies on prostate cancer PBT are needed to assess quality of life and socioeconomic factors.
• Early positive results exist for chemoproton therapy in lung, esophageal, and pancreatic cancers.

Conclusions:

• Proton beam therapy offers significant advantages in reducing radiation exposure for specific cancers, particularly in pediatrics and head/neck regions.
• Further clinical research is essential for chemoproton therapy and for addressing cost and national insurance considerations in Japan.
• Optimizing PBT use requires continued study to balance high cure rates with patient quality of life.